Â
Latest Bioresorbable Scaffolds Companies Update
Abbott Acquires MitraClip Company, Tendyne Holdings strategic move by Abbott in December 2023 strengthens their position in the transcatheter tricuspid valve replacement (TTVR) market and expands their portfolio of bioresorbable technologies.
Biotronik Partners with Elixir Medical to Develop Novel Bioresorbable Scaffolds for Coronary Artery Disease collaboration announced in January 2024 combines Biotronik's expertise in vascular stents with Elixir Medical's innovative bioresorbable materials to create next-generation scaffolds for treating coronary artery blockages.
Boston Scientific Launches Absorb GTR Bioresorbable Scaffold System in Europe: This December 2023 launch expands patient access to Boston Scientific's bioresorbable scaffold technology for treating peripheral artery disease (PAD).
REVA Medical Announces First Implant of their Revita Resorbable Coronary Scaffold System: This November 2023 milestone marks a significant step forward for REVA Medical in bringing their bioresorbable scaffold technology to the market.
List of Bioresorbable Scaffolds Key Companies in the Market
- Abbott (US)
- Medtronic (UK)
- Boston Scientific Corporation (US)
- Biotronik (Germany)
- Elixir Medical Corporation (US)
- REVA Medical, Inc (US)
- Amaranth Medical, Inc. (US)
- Kyoto Medical Planning Co. Ltd. (Japan)
- Xenogenics Corporation (US)
- B. Braun (Germany)
- Cardinal Health. (US)
- Lombard Medical, Inc (UK)
- Translumina (Germany)
- MicroPort Scientific Corporation (China)
- TERUMO CORPORATION (Japan).